Qu et al. [98,101] developed EpCAM-conjugated mesoporous silica nanoparticles (EpCMSN) to effectively deliver carboplatin (CRB) for the treatment of retinoblastoma (RB), a rare eye tumor. Here, EPCAM is linked to retinoblastoma.